mpact is the name of the p3 trial that showed adding abraxane to gemcitabine increased median survival over gemcitabine by itself. It’s published. Yes abraxane was approved in pancreatic cancer based on mpact.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-10
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
-0.001(1.47%) |
Mkt cap ! $18.19M | |||
| Open | High | Low | Value | Volume |
| 6.7¢ | 7.0¢ | 6.7¢ | $95 | 1.411K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12728 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 21327 | 1 |
View Market Depth
| Last trade - 15.59pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.001 ( 1.47 %) |
||||
| Open | High | Low | Volume | ||
| 6.7¢ | 6.9¢ | 6.7¢ | 333 | ||
| Last updated 15.48pm 14/06/2024 ? | |||||
| ATX (ASX) Chart |